A Randomized Controlled Trial Evaluating 5-aminolevulinic Acid Photodynamic Therapy With Different Incubation Times for the Treatment of Actinic Keratosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Change in number of Actinic Keratosis (AK) lesions
研究概览
简要总结
This is a randomized clinical trial evaluating blue light 5-aminolevulinic acid (ALA) photodynamic therapy with different incubation times for the treatment of actinic keratosis.
Subjects who are interested in participating, currently living in the Chicago metropolitan area, and meet inclusion and exclusion criteria will be enrolled in the study. Subjects will be randomized to either 1) zero time ALA incubation or 2) 1 hour ALA incubation. Demographic and health data will be collected prior to treatment initiation. Three visits will be conducted: screening, treatment, and follow up visit at 8 weeks.
This study is a pilot study designed to determine feasibility of this procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who have been diagnosed with actinic keratosis.
- •Subjects who by the investigator deem to be suitable for photodynamic therapy of the face or scalp.
- •Males or females ≥ 18 years old
- •Fitzpatrick skin types I-VI
- •Subjects are in good health as judged by the investigator.
- •Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.
排除标准
- •Subjects who by the investigator are not suitable for photodynamic therapy.
- •Lesions suspicious or proven for skin cancer
- •History of 2 or more ALA- PDT treatments within the past 6 months.
- •Use of keratolytics within 2 days of initiation of treatment (e.g., >5% urea, glycolic acid, lactic acid, salicyclic acid)
- •Cryotherapy within the past 2 weeks.
- •Topical retinoids within the past 4 weeks
- •Procedures, such as microdermabrasion, ablative lasers, ALA-PDT, chemical peels, 5-fluorouraci, diclofenac, imiquimod within the past 8 weeks
- •Systemic retinoids within the past 6 months
- •Pregnant or breast feeding
- •Uncooperative subjects or subjects with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
- •Subjects who are unable to understand the protocol or give informed consent.
- •Subjects who in the opinion of the investigator are not suitable for the study.
研究组 & 干预措施
One hour incubation with ALA (5-aminolevulinic acid)
Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
干预措施: Blue light therapy (Device)
Zero incubation with ALA (5-aminolevulinic acid)
Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
干预措施: ALA (5-aminolevulinic acid) (Drug)
Zero incubation with ALA (5-aminolevulinic acid)
Subjects will receive zero time of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
干预措施: Blue light therapy (Device)
One hour incubation with ALA (5-aminolevulinic acid)
Subjects will receive one hour of incubation with ALA (5-aminolevulinic acid) before photodynamic blue light therapy.
干预措施: ALA (5-aminolevulinic acid) (Drug)
结局指标
主要结局
Change in number of Actinic Keratosis (AK) lesions
时间窗: Baseline and 8 Weeks
The number of AK lesions will be counted by a live, blinded assessor at baseline and at Week 8 follow-up visit.
次要结局
未报告次要终点
研究者
Murad Alam
Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery
Northwestern University